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Abstract
Previously we have shown that compacted DNA nanoparticles can drive high levels of transgene expression after subretinal
injection in the mouse eye. Here we delivered compacted DNA nanoparticles containing a therapeutic gene to the retinas of
a mouse model of retinitis pigmentosa. Nanoparticles containing the wild-type retinal degeneration slow (Rds) gene were
injected into the subretinal space of rds
+/2 mice on postnatal day 5. Gene expression was sustained for up to four months at
levels up to four times higher than in controls injected with saline or naked DNA. The nanoparticles were taken up into
virtually all photoreceptors and mediated significant structural and biochemical rescue of the disease without histological or
functional evidence of toxicity. Electroretinogram recordings showed that nanoparticle-mediated gene transfer restored
cone function to a near-normal level in contrast to transfer of naked plasmid DNA. Rod function was also improved. These
findings demonstrate that compacted DNA nanoparticles represent a viable option for development of gene-based
interventions for ocular diseases and obviate major barriers commonly encountered with non-viral based therapies.
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Introduction
Gene therapy represents, in theory, the ultimate desirable
strategy for long-term treatment of inherited retinal diseases. Viral
delivery of exogenous genes has been used successfully in the eye
for the treatment of inherited blinding diseases in mice and dogs
[1–4]. Non-viral delivery methods represent an additional
therapeutic strategy, but historically these approaches have been
limited by inefficient entrance of the genetic material into the
target cells and by attenuated duration of transgene expression
[5,6]. In the present study, we have adopted a non-viral gene
transfer strategy designed to overcome these barriers. Our
approach is to use single-molecule DNA nanoparticles in which
plasmid DNA is compacted by polyethylene glycol (PEG)-
substituted 30-mer lysine peptides (CK30PEG). These particles
have several advantages over traditional non-viral approaches:
they are versatile, small in size, easy to prepare, have large vector
capacity (up to 20 kb), are stable in nuclease-rich environments,
and have high transfectivity [7–11]. Their high transfectivity is
due, in part, to the small particle size (diameter,8 nm [9,10]) and
also to specific interactions with cell-surface nucleolin and
subsequent non-degradative trafficking to the nucleus [12]. These
nanoparticles can successfully transfect both dividing and non-
dividing cells, and have been shown to be effective agents, both in
experimental models as well as in a phase I/IIa clinical trial for
cystic fibrosis, in delivering genes of interest to multiple tissues,
including the lung, retina, and brain [7,8,10,11,13–15]. Such
nanoparticles are non-inflammatory, non-immunogenic [7,14,16],
and our own proof-of-principle studies have demonstrated that
they are non-toxic in the eye [13].
Recently, we showed that CK30PEG nanoparticles containing
a CMV-EGFP plasmid could be used to safely and efficiently
transfer genes to the eyes of adult wild-type (WT) mice [13]. The
high ocular transfectivity of the particles is evident in our
observation that nearly all retinal photoreceptor cells were
transfected (in multiple regions examined), not just those cells
near the site of injection. Furthermore, gene expression levels
could be titrated to mimic the expression levels of native
photoreceptor genes. Based on our initial results and those of
others, this strategy appears to be a good candidate for the delivery
of therapeutic genes to rescue hereditary ocular diseases.
We chose to use a murine model of retinitis pigmentosa (the
rds
+/2 mouse) for our first disease rescue studies. The protein
product of this gene, RDS (retinal degeneration slow; also called
Peripherin/rds or Peripherin 2), is a tetraspanin glycoprotein
known to form homomeric complexes as well as heteromeric
complexes with a related tetraspanin protein, rod outer segment
membrane protein 1 (ROM-1). RDS is photoreceptor-specific and
PLoS ONE | www.plosone.org 1 April 2009 | Volume 4 | Issue 4 | e5290is critical for photoreceptor disc rim assembly, outer segment (OS)
orientation, photoreceptor structural stability, and OS disc
renewal [17–19]. Over 80 different mutations in the RDS gene
have been identified in humans and are associated with multiple
retinal diseases, including autosomal dominant retinitis pigmen-
tosa (adRP) and progressive macular degeneration (MD) [20–23].
Unlike the retina in the homozygous (rds
2/2) mouse, which fails to
form OSs and undergoes fairly rapid apoptotic photoreceptor cell
death, the retina in the heterozygous (rds
+/2) mouse exhibits a
classic, well-defined adRP phenotype characterized by early onset
rod degeneration and late onset cone degeneration. Furthermore,
the OSs of the rds
+/2 are highly disordered, malformed, and short
(compared to normal OSs), are electrophysiologically deficient,
and express reduced levels of key phototransduction proteins [24–
27]. Of relevance to our strategy of gene supplementation, we and
others have shown that expression of at least 80% of the normal
amount of RDS is necessary in order to build proper photore-
ceptor OSs [24,28].
The purpose of the current study was to test the efficacy of
CK30PEG nanoparticles with regard to their ability to rescue the
rds
+/2 phenotype as a prelude to optimization of this technology for
the treatment of human hereditary eye diseases. It is known that the
rds model is challenging to rescue, because of the severe structural
defect associated with the complete absence of RDS protein [26],
and few groups are using it as a gene therapy model in spite of the
multitude of RDS-associated diseases. One other group has
documented partial rescue of an rds model with gene transfer
therapy using an AAV vector [29–31], and we have shown that the
disease phenotype can be rescued by transgenesis [24]. Here we
present results showing that compacted DNA-nanoparticles con-
taining the Rds gene are capable of achieving significant rescue of
the disease phenotype in the rds
+/2 adRP model.
Results
Rds nanoparticles drive high and persistent transgene
expression
RDS expression and localization to the distal connecting cilium
in the mouse rod photoreceptor cell begin around postnatal day 5
(P5) [26,32] (i.e., before OS formation), a time that precedes the
onset of retinal degeneration in the rds model. Hence, we selected
P5 as the physiologically appropriate developmental stage for
therapeutic intervention. Two vectors were generated, each
expressing the full-length cDNA of normal mouse peripherin/rds
(NMP), one under the control of the ubiquitously expressed
chicken beta-actin promoter (CBA), and the other employing the
well characterized photoreceptor-specific promoter for the human
interphotoreceptor retinoid-binding protein (IRBP) [33]. Acetate
compacted nanoparticles containing the vectors (Figure S1) or
controls were injected subretinally into rds
+/2 mice at P5 and
followed for up to four months. The controls chosen for this study
were saline (vehicle) and uncompacted plasmid DNA (called
‘‘naked DNA’’) carrying the same therapeutic transgene (CBA-
NMP or IRBP-NMP).
As shown in Figure 1, injection of both CBA-NMP and IRBP-
NMP nanoparticles resulted in significantly elevated expression of
Rds message, as measured by qRT-PCR. At post-injection day 2
(PI-2), mRNA levels in CBA-NMP and IRBP-NMP nanoparticle-
injected eyes were at least three- to four-fold higher than the saline
or naked DNA-injected eyes (Figure 1). Eyes injected with IRBP-
NMP maintained elevated expression until PI-14, then stabilized
at levels two- to three-fold higher than controls, while eyes injected
with CBA-NMP stabilized at similar levels at PI-7. Neither saline
nor naked DNA produced a significant alteration in Rds mRNA
levels (Figure 1A), compared to uninjected eyes. Elevated mRNA
levels were maintained for up to four months (PI-120), the longest
time point examined.
Compacted DNA nanoparticles efficiently transfer RDS to
all photoreceptor cells
We next examined the identity of the cells that took up the
exogenously delivered NMP cDNA and the efficiency of gene
product expression within the retina over time, using immunohis-
tochemistry. The entire eye was cut and every sixth section was
collected and assessed, enabling us to examine gene expression in
multiple regions throughout the retina. Due to an epitopic
modification in the NMP carboxyl terminus (P341Q), which is
not present in wildtype RDS and does not result in retinal disease
or vision loss [24], the transferred Rds gene product can be
Figure 1. Injection of NMP nanoparticles into P5 rds
+/2 animals
increases Rds mRNA levels. cDNA from eyes injected with saline,
naked DNA (A) or nanoparticle DNA (B) at PI-2 through PI-120 was
prepared and analyzed by qRT-PCR to determine relative Rds mRNA
levels. Because Rds primers amplify from the NMP (nanoparticle) and
the WT (endogenous) allele but not from the Rds mutant allele,
expression values are reported as fold change from the uninjected
contralateral control eye. Values shown are averages6S.D. (N=3–6
mice per group). (A) Injection of saline or naked DNA does not alter Rds
message levels at any time point. (B) Conversely, injection of both CBA-
NMP and IRBP-NMP compacted DNA nanoparticles leads to a
significant, two- to four-fold increase in total Rds message level
compared to the naked DNA injected eyes (*p,0.001, **p,0.05. This
increase persists through the last time point examined (PI-120).
doi:10.1371/journal.pone.0005290.g001
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monoclonal antibody (mAB 3B6) that recognizes the P341Q
epitope. [For demonstration of the selectivity of mAB 3B6 for
transferred RDS (NMP) as opposed to native (endogenous RDS),
see Figure S2 and our previous publications [24,34].] The
endogenous mouse RDS protein (and to a much lesser extent
transgenic NMP protein) is labeled with the RDS-CT antibody
[35]. Although normal OS development has not yet begun at P7
(PI-2) [36], Figure 2 (top row) shows expression of both transferred
(Figure 2A and 2B) and native RDS (Figure 2C) protein in the tip
of the photoreceptors. By PI-7 (P12), distinct outer and inner
nuclear layers are apparent and NMP/RDS staining in the tips of
nascent OSs is visible as a thin immunopositive layer adjacent to
the photoreceptor nuclei. NMP distribution in the OSs persisted
through the latest time point examined (PI-30). NMP also co-
localized with native RDS and was usually limited to the OS layer
(Figure 2); no NMP was detected in eyes injected with saline
(Figure 2C and Figure S3) or naked DNA (not shown).
Occasionally, NMP expression was detected in RPE cells after
nanoparticle injection (Figure 2). Expression in the RPE was
highly variable; while many animals had some RPE expression,
others did not. RPE expression was much more common in eyes
injected with CBA-NMP nanoparticles, consistent with its role as a
ubiquitous promoter. On the other hand, IRBP-NMP staining in
the RPE was almost always limited to PI-2. NMP detection with
mAB 3B6 in the OSs was heterogeneous, with stronger signal in
areas closer to the injection sites. However, we estimate that a
majority of photoreceptors expressed the product of the trans-
ferred gene (based on a qualitative assessment of mAB 3B6
immunostaining in successive retinal sections). The choice of
promoter did not have any apparent effect on cellular distribution
within the photoreceptor: both CBA-NMP and IRBP-NMP
nanoparticles exhibited similar distribution patterns at all time
points examined.
Rds nanoparticles improve expression levels of key visual
transduction proteins
Our next step was to determine whether nanoparticle-driven
expression of NMP results in rescue of the rds
+/2 disease phenotype.
To measure biochemical rescue, we assayed the levels of several
photoreceptor-specific proteins known to be decreased by RDS
deficiency. Figure 3 (panels A and D) shows that expression levels of
the RDS binding partner ROM-1 were increased, both in terms of
message (by qRT-PCR) and protein (by Western blot analysis),
compared to uninjected controls, at PI-30. Consistent with the
mRNA data presented in Figure 1, expression of RDS protein was
also increased in NMP nanoparticle-injected eyes. Expression of
rhodopsin (the rod visual pigment) is necessary for phototransduc-
tion and proper photoreceptor maintenance, and is significantly
decreased in the rds
+/2 retina [37]. We show that injection of NMP
nanoparticles led to increased rhodopsin message (Figure 3B) and
protein (Figure 3E) levels. We also observed a similar increase in the
message level of short-wavelength cone opsin (S-opsin, Figure 3C)
after nanoparticle injection, although no alteration in S-opsin
protein level was detected (Figure 3F), likely due to lack of cone
degeneration at this age.
Since the photoreceptor population in the mouse retina consists
of 95–97% rods [38,39], the results presented in Figure 2 are
consistent with the conclusion that the two types of nanoparticles
drove gene expression in rods and that their products were
delivered with fidelity to the OS. However, it was not clear from
those data whether transferred RDS protein was expressed in
cones. Therefore, double labeling for NMP and S-opsin was
performed on PI-30 eyes. Two representative cones from each
nanoparticle-injected and control eye are shown in Figure 3G
(single, 0.5-mm slices of spinning disk confocal image stacks). Most
cones from nanoparticle-injected eyes expressed NMP when
consective sections were evaluated from the same eye. S-opsin
immunopositive cone cells that lacked NMP expression were
Figure 2. Transferred NMP co-localizes with endogenous RDS. Frozen retinal sections from eyes collected at multiple ages (PI-2 to PI-30) were
immunostained for NMP (mAB 3B6, green) and total RDS (RDS-CT, red) with a nuclear counterstain (DAPI, blue). Transferred RDS from eyes injected
with CBA-NMP (A) and IRBP-NMP (B) nanoparticles is detected at PI-2. Expression remains strong through the latest time point analyzed (PI-30) and
co-localizes with native RDS. Expression is limited to the OSs or nascent OSs and is not detected in any other retinal cell types, subcellular
compartments or layers. (C) No NMP is detected in saline-injected control eyes, but native RDS is detected beginning at PI-2 (P7), consistent with
normal ocular development. Scale bars, 20 mm. N=3–5 mice per group. Abbreviations: RPE, retinal pigment epithelium; OS, outer segment layer;
ONL, outer nuclear layer; INL, inner nuclear layer.
doi:10.1371/journal.pone.0005290.g002
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+/2 retina. (A–C) cDNA was
collected at PI-30, and message levels of photoreceptor genes were analyzed by qRT-PCR. (A) CBA-NMP nanoparticle injection leads to a modest
increase in Rom-1 message levels, while IRBP-NMP nanoparticle injection increases expression four- to five-fold over levels in uninjected control eyes.
(B,C) CBA-NMP and IRBP-NMP nanoparticle injections lead to increases in rod (B) and cone (C) opsins. (A–C); N=3 animals per group. (D–F) Protein
levels at PI-30 after nanoparticle injection were examined. Representative SDS-PAGE/Western blots from individual retinas are shown (N=5–6 animals
Nanoparticles in the rds
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positive cells were detected in saline-injected eyes (Figure 3G,
bottom row).
Nanoparticle-driven Rds expression restores retinal
function
The rds
+/2 mouse adRP model exhibits reduced electroretino-
gram (ERG) responses indicative of early-onset slow rod
degeneration followed by late-onset slow cone degeneration
[26,40]. In order to assess functional rescue of this phenotype
after treatment, full-field ERGs were obtained from nanoparticle-
injected and control mice. Initial ERGs were obtained and
analyzed at PI-30 (see Table 1). Average scotopic a-wave
amplitudes, indicative of rod function, were increased with
statistical significance after injection of either CBA-NMP or
IRBP-NMP nanoparticles, compared to amplitudes from eyes
injected with naked DNA or saline. In order to confirm that the
naked DNA had no adverse effect, a subset of animals was injected
with saline only. Scotopic a-wave amplitudes for saline injected
animals were not significantly different from those injected with
either CBA-NMP or IRBP-NMP naked DNA (p=0.2634).
Interestingly, nanoparticles led to an improvement in cone
function. The magnitude of rescue varied considerably with both
nanoparticles, most likely due to variations in particle uptake and/
or relative activity of CBA vs. IRBP promoters in rods and cones.
Several nanoparticle-injected animals exhibited significantly
greater-than-average rescue; 6/15 (IRBP-NMP) and 5/19 (CBA-
NMP) treated animals had 90% increase in scotopic a-wave
amplitudes, compared to naked DNA-injected controls. Similarly,
4/15 (IRBP-NMP) and 6/19 (CBA-NMP) animals had at least a
70% increase in cone ERG amplitudes.
Although WT eyes can completely recover from P5 subretinal
injections, we observed that ERG amplitudes from saline- and
naked DNA-injected eyes in the rds
+/2 tended to be lower than in
uninjected eyes (data not shown). These data, in combination with
our earlier work on adult rds
+/2 mice [41], suggest that the rds
+/2
eye is more fragile than the normal eye and that subretinal
injections per se in the mutant may cause adverse effects on visual
function which would need to be overcome by any treatment. This
idea is further supported by the wide variation in nanoparticle-
mediated functional rescue, and highlights the need to assess
rescue in every treated animal.
In order to determine whether functional rescue persisted at
later timepoints, animals that demonstrated the hallmarks of
rescue at PI-30 were selected for follow-up at PI-60 and PI-120
(Table 1 and Figure 4). Injection of CBA-NMP nanoparticles did
not result in long-term functional rescue of rods (Table 1, and
Figure 4A, bottom) or cones (Table 1, and Figure 4C, bottom). In
striking contrast, ERG amplitudes from IRBP-NMP nanoparticle-
injected eyes continued to be elevated at both PI-60 and PI-120
when compared to naked DNA-injected controls (Table 1, and
Figure 4B and 4D, bottom). Cone function continued improving
Table 1. Average full-field ERG values at various timepoints.









Scotopic-A CBA-NMP 134.8613.3 19 92.969.4 6 41.9 mV, 45.1% 0.018
IRBP-NMP 146.7613.7 15 96.0611.0 9 50.7 mV, 52.8% 0.018
Photopic-B CBA-NMP 148.1611.3 19 98.7615.2 6 49.4 mV, 50.1% 0.035
IRBP-NMP 134.4613.7 15 92.469.7 9 42.0 mV, 45.4% 0.040
PI-60
Scotopic-A CBA-NMP 107.767.8 5 81.8617.2 4 25.9 mV, 31.7% 0.061
IRBP-NMP 148.468.9 10 70.5618.8 4 77.9 mV, 110.4% 0.011
Photopic-B CBA-NMP 117.3619.7 5 131.0611.3 4 213.7 mV, 211.5% 0.594
IRBP-NMP 194.8616.0 10 64.5620.4 4 130.3 mV, 202.0% 0.0007
PI-120
Scotopic-A CBA-NMP 123.9612.9 5 77.1617.3 6 46.8 mV, 60.7% 0.086
IRBP-NMP 129.469.6 5 67.6616.2 5 61.8 mV, 91.4% 0.011
Photopic-B CBA-NMP 120.8614.83 5 108.0613.48 6 12.8 mV, 11.8% 0.54
IRBP-NMP 185.6620.6 5 87.9620.5 5 97.7 mV, 111.1% 0.009
aValues are mean mV6S.E.M.
bComparison between nanoparticle and naked DNA using 2-tailed un-paired Student’s t-test as described in methods.
cNumber of animals tested.
doi:10.1371/journal.pone.0005290.t001
per group). (D) CBA-NMP and IRBP-NMP nanoparticle injections increase RDS and ROM-1 protein levels (protein load: 20 mg per lane). (E) Increases in
rhodopsin protein (RHO) are detected after injection of both CBA-NMP and IRBP-NMP nanoparticles (protein load: 10 mg per lane). (F) No change in S-
opsin (S-ops) protein level is detected after nanoparticle injection (protein load: 50 mg per lane). (G) Double immunolabeling for transferred RDS
(mAB 3B6, green) and cone OSs (S-opsin, red) with nuclear counterstain (DAPI, blue) was performed on frozen sections from PI-30 eyes.
Representative cones from two different animals are shown for each treatment. Cones in eyes injected with CBA-NMP or IRBP-NMP nanoparticles
express transferred NMP (top and middle rows). Saline injected eyes express no transferred NMP (bottom row). Scale bar, 5 mm; N=3–5 animals per
treatment group. Abbreviations: OS, outer segment layer; IS, inner segment layer; ONL, outer nuclear layer *=p,0.05.
doi:10.1371/journal.pone.0005290.g003
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levels at PI-120; based on two-way ANOVA, age was not an
interacting factor in any case. In addition to the overall (average)
improvement in cone ERG function at PI-120, in 6/10 (PI-60) and
2/5 (PI-120) cases IRBP-NMP nanoparticle injection led to
photopic ERG levels that exceeded the mean value for uninjected
WT animals (for example, at PI-120, treated subject 1, 245.6 mV
vs. age-matched WT average 204.9624.5 mv, N=8). This suggests
that IRBP-NMP nanoparticle-mediated NMP expression is
capable of overcoming damage due to subretinal injection and
can slow or rescue the functional degeneration associated with
RDS haploinsufficiency.
Figure 4. Expression of transferred NMP leads to partial functional rescue of the rds
+/2phenotype. A subset of individual injected
animals identified from PI-30 ERG analysis (Table 1) was chosen for follow-up. (A,B) Top: scotopic traces from naked DNA (gray) and nanoparticle
(black) injected eyes at PI-30. Bottom: (A) Scotopic a-wave amplitudes from eyes injected with CBA-NMP nanoparticles are elevated at PI-30, but drop
almost back to baseline at PI-60 and PI-120. (B) IRBP-NMP nanoparticle-injected animals retain improved rod function (as measured by scotopic a-
wave) through PI-120. (C,D) Top: photopic traces from naked DNA (gray) and nanoparticle (black) injected eyes at PI-30. Bottom: (C) Cone function (as
measured by photopic b-wave) does not remain substantially improved past PI-30 in eyes injected with CBA-NMP nanoparticles. (D) Photopic b-wave
amplitudes in IRBP-NMP nanoparticle-injected animals are improved at PI-30 and continue improving at PI-60 (*=p,0.05, PI-30 vs. PI-60) before
stabilizing at the last time point examined (PI-120). Amplitudes are means6standard error (N values are in Table 1).
doi:10.1371/journal.pone.0005290.g004
Nanoparticles in the rds
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Rds expression
Finally, we analyzed NMP nanoparticle-mediated structural
rescue of photoreceptors in the rds
+/2 retina, using both light and
electron microscopy, at PI-30 and PI-120, in comparison with
uninjected controls. Photoreceptors in the rds
+/2 retina typically
exhibit very short OSs with misaligned and whorl-like disc
membranes. At PI-30, there was a modest increase in outer
nuclear layer (ONL) thickness (Fig 5A, top), and many individual
OSs exhibit improved ultrastructure (arrows, Figure 5A, bottom).
By PI-120, however, virtually all photoreceptors examined showed
noticeable structural improvement (Figure 5B). Consistent with the
ERG results (see Figure 4), structural rescue was more pronounced
in the IRBP-NMP-injected eyes compared to CBA-NMP-injected
eyes at PI-120, but both exhibited OSs with orderly stacks of disc
membranes.
In order to determine the extent of these structural improve-
ments, we undertook a series of morphometric analyses of the
nanoparticle injected-eyes compared to controls. Histological
images were collected from each eye at 200 mm, 400 mm, and
600 mm from the optic nerve head (both temporally and nasally)
and vertical rows of ONL nuclei and OS thickness were measured.
Figure S4 shows results from two representative experimental
animals, with the average values (6 standard deviation) obtained
from uninjected control eyes shaded in gray (accompanying
supplemental methods found in Text S1). At PI-30, injected
animals showed little or no increase in the number of rows in the
ONL (top panels), but a definite increase in OS thickness (bottom
panels). At PI-120, there was no morphometric evidence of any
histological benefit from the CBA-NMP nanoparticles, while
IRBP-NMP nanoparticles led to a slight increase in both the
number of rows in the ONL and in OS thickness. The increase in
ONL rows at PI-120 is particularly relevant, since it suggests that
nanoparticle-mediated increases in RDS may slow photoreceptor
cell death in the rds
+/2.
Discussion
This study demonstrates significant rescue of an ocular disease
phenotype with a non-viral gene delivery method. Our data
indicate that ocular delivery of compacted DNA-nanoparticles
carrying Rds cDNA at P5 results in transgene expression that is: a)
rapid-onset (starts at PI-2) and high with levels elevated up to four-
fold above the endogenous, b) widely distributed in all photore-
ceptors, c) properly localized to the OSs of rods and cones, and d)
persistently detected up to 4 months post- treatment without any
obvious adverse side effects. Nanoparticle injection also improved
expression of key photoreceptor-specific proteins known to be
affected by the ongoing photoreceptor degeneration in the rds
+/2
retina. Notably, IRBP-NMP nanoparticles afforded significant and
persistent restoration of both rod and cone function, with full-field
cone ERG amplitudes approaching those seen in WT mice.
Ultrastructural rescue in nanoparticle-injected eyes was similarly
pronounced; at four months post- treatment, IRBP-NMP animals
exhibited properly oriented OSs with well-aligned discs.
Viral gene therapy has been remarkably successful in treating
some types of ocular diseases, the most notable example of which
to date being the AAV-mediated long-term rescue of vision in
Briard dogs harboring a mutation in RPE65 [1,2]. Results from
these studies have prompted three successful and ongoing human
clinical trials [42–44]. However, the development of effective non-
viral vectors is a prudent step as an alternative to more traditional
methods. While a number of non-viral approaches have been
explored, including the use of liposomes, electroporation of naked
DNA, and gene delivery with dendrimers, they have encountered
persistent problems with limited uptake and short-term gene
expression [6], although advances in this area have been made
[45]. Therefore, we chose to test the efficacy of compacted DNA
nanoparticles comprised of PEG-substituted lysine peptides for
gene delivery. We show here that these nanoparticles represent a
significant improvement over other non-viral vectors in terms of
transgene uptake and stability of expression (elevated levels
detected to the latest timepoint examined PI-120). Furthermore,
we show partial morphological and functional rescue of the rds
+/2
model. Because of the structural defects that accompany Rds
mutations or deficiency, rescue of the disease phenotype
heretofore has been particularly difficult [29–31]. However, since
most Rds-associated RP in humans is due to loss-of-function
mutations causing a haploinsufficiency phenotype, the rds
+/2 is a
relevant model to target.
Figure 5. Transferred NMP leads to structural rescue of the rds
+/2 phenotype. Light micrographs (top row) and electron micrographs
(bottom row, N=3–5 animals per group) from rds
+/2 were examined. (A) At PI-30, moderate ultrastructural rescue is detected in the OSs of
nanoparticle injected eyes (arrows). (B) By PI-120 significant ultrastructural improvement in OSs of nanoparticle injected eyes is apparent. OS discs are
properly aligned and flattened and OS do not exhibit the swirl-like structures typical of the rds
+/2. RPE, retinal pigment epithelium; OS, outer segment
layer; IS, inner segment layer; ONL, outer nuclear layer. Scale bar, 10 mm.
doi:10.1371/journal.pone.0005290.g005
Nanoparticles in the rds
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in this study we chose two other well-studied promoters to drive
transgene expression: one is a ubiquitously expressed promoter
(CBA), while the other is tissue-specific (IRBP). One of our goals
was to see which of these two promoters would provide the best
transfectivity and rescue. Based on previous studies using these
promoters in the eye, we initially hypothesized that the IRBP
promoter would drive modest expression selectively in rods and
cones [33], while the CBA promoter would direct high expression
levels in multiple ocular cell types. Although the CBA promoter
has been shown to drive GFP expression in most ocular tissues
soon after injection, it has also been documented to dictate a more
restricted distribution of tissue-specific genes in the eye [46]. Our
study confirmed this latter point; the product of CBA-NMP-driven
transgene expression was almost exclusively detected in the
photoreceptor OSs, with occasional expression in the RPE. This
more specific tissue distribution is likely due to the rapid turnover
of any ectopically expressed protein.
IRBP-mediated NMP expression was detected in rods and
cones, but immunohistochemistry revealed that while most cones
expressed the transferred gene, some did not. The reason for this
variation is not known, but it is possible that cones differentially
express the nucleolin cell-surface protein known to mediate uptake
of the nanoparticles [12]; alternatively, heterogeneity in the
response to the injection insult may affect NMP expression/
uptake. In spite of variation in nanoparticle-driven gene expression
in cones, we observed essentially complete functional cone
recovery (to WT levels) in many IRBP-NMP treated animals.
Cone rescue is likely of greater magnitude than rod rescue because
cones need less RDS to form fully functional OS than do rods
[24]. Furthermore, the RDS haploinsufficiency phenotype is much
less severe in cones than in rods, and we have recently
demonstrated a differential role for RDS in the two photoreceptor
types [47].
Due to the more pronounced functional and structural rescue in
eyes treated with IRBP-NMP nanoparticles (compared to CBA-
NMP), we conclude that IRBP is the preferred promoter for this
application and will take advantage of this finding in future studies
directed at therapeutic intervention in hereditary photoreceptor
degenerations. It is not clear to us why IRBP-NMP particles lead
to more pronounced cone rescue than do CBA-NMP particles in
spite of demonstrating similar levels of mRNA expression
(Figure 1), but it is possible that the two transcripts are differently
regulated. While the IRBP promoter drives gene expression in
both rods and cones, qualitative results from transgenic mice made
with the same transgene as the IRBP-NMP nanoparticles (Figure
S5 and [24]) suggest that IRBP-mediated gene expression is much
higher in cones than in rods. The enhanced cone rescue in IRBP-
NMP (compared to CBA-NMP) treated eyes is likely a result of this
inherent ability of the IRBP promoter to drive higher transgene
expression in cones.
We chose to treat our animals at P5 both because it represents a
physiologically appropriate intervention time and because previ-
ous rds gene therapy trials have reported difficulties correcting the
ERG defect in adult rds mice, whereas correction was observed
following neonatal gene transfer [30,31]. The high rates of
transfectivity we report here after P5 injection of rds
+/2 mice
combined with the high rates of transfectivity we previously
reported after subretinal injection in adult WT mice [13] show
that these DNA-nanoparticles can effectively transfect both mitotic
and post-mitotic (terminally differentiated) retinal cells. Further-
more, our ability to drive long-term expression (up to four months)
suggests that CK30PEG-compacted DNA-nanoparticles may not
be subject to some of the practical impediments that have limited
the utility of other forms of non-viral gene therapy. We have
shown partial structural and functional rescue of the rds
+/2
phenotype by delivery of compacted DNA-nanoparticles contain-
ing WT Rds. These nanoparticles offer a promising gene therapy
modality that, with further development, may find practical




All animal procedures were approved by the University of
Oklahoma Health Science Center Institutional Animal Care and
Use Committee (IACUC) and adhered to the ARVO Statement
for the Use of Animals in Ophthalmic and Vision Research (see
Policies, http://www.arvo.org/).
Vector and nanoparticle construction
Two constructs were generated expressing the full-length mouse
Rds cDNA (1.7 kb) containing the P341Q modification (called
NMP), for specific detection with the mAB 3B6 monoclonal
antibody [18]. Either the human interphotoreceptor retinoid-
binding protein (IRBP) promoter (1.3 kb) [33] or the chicken beta-
actin (CBA) promoter (280 bp) was used to drive NMP expression.
The two promoter regions were amplified from genomic DNA by
PCR, sequenced, and then sub-cloned into the pXL-TOPO vector
in front of NMP using EcoR I and BamH I restriction enzymes.
The two plasmid DNAs were individually compacted into rod-like
acetate nanoparticles (Figure S1) at Copernicus Therapeutics as
reported previously [12,13], and were used at a final concentration
of 3.06 mg/ml in 0.9% saline.
Subretinal injections
Mice (rds
+/2 pups at P5) were anesthetized by incubation on ice
for 2–2.5 minutes. The eyelid of the right eye was cut, the cornea
was exposed, and a puncture in the cornea was made with a sterile
30-gauge needle. A 35-gauge blunt-end needle attached to a 10 ml
NanofilH syringe (World Precision Instruments, Sarasota FL) was
inserted into the puncture under an operating microscope (Carl
Zeiss Surgical, Inc., NY). A volume (0.3 ml) of solution containing
fluorescein dye and either nanoparticles, saline (vehicle), or naked
DNA was delivered into the subretinal space, usually in the
superior temporal quadrant. Since the retina is not fully developed
at this age, some injected material is likely released into the
vitreous, although the site of injection is subretinal. After injection,
the needle was left in place for 3–5 seconds to allow full treatment
delivery before being withdrawn gently. Successful delivery of
material was confirmed by observation of subretinal yellow-green
fluorescence at the time of injection. The cut eyelid was returned
to its original position and the surface of the eye was gently blotted
with a Kimwipe. Animals were warmed on a temperature-
controlled (37uC) bed until fully awake. All nanoparticles and
uncompacted plasmid DNA (naked DNA) were used at the same
concentration (3.06 mg/ml), selected based on data from our
previous study [13]. Because the compaction process relies on the
presence of DNA, there is no ‘‘empty’’ nanoparticle, so controls
were limited to saline and naked DNA carrying the same
therapeutic vector as the nanoparticles. If material delivery could
not be confirmed, or if microphthalmia or signs of intraocular
infection were observed, the injection was considered unsuccessful
and the animal was removed from the study (121/432,28%).
Mice were maintained in the breeding colony under cyclic light
(14-hour light/10-hour dark) conditions; cage illumination was
approximately 7 foot-candles during the light cycle.
Nanoparticles in the rds
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Both injected and uninjected whole eyes were collected at PI-2, 7,
14, 21, 30, and 120 days for analysis of mRNA levels. qRT-PCR
was performed with a MyIQ single-color qRT-PCR machine (Bio-
Rad). Mice were euthanized, eyes were enucleated and homoge-
nized and total RNA was extracted using TRIzol (Invitrogen Inc.
Carlsbad, CA) as described previously [13]. Subsequently, DNase
treatment was performed with RNase-free DNase (Promega Inc.) to
remove both genomic DNA and any remaining nanoparticle DNA.
cDNA synthesis by reverse transcription was performed and 20 ng
of cDNA from each sample was used for qPCR. Rds primer
sequenceswerereported previously [13].Melting curveanalysisand
agarose gel electrophoresis were performed at the end of the
reaction to ensure that the PCR products were specific and of
appropriate size. All experimental mRNA levels were quantified
against the housekeeping gene hypoxanthine phosphoribosyltrans-
ferase (HPRT) as described previously [13]. Relative expression
levels were calculated by the 2
2DcT method [48]. At least three
injected and three uninjected eyes from each treatment group at
each of the scheduled time points were analyzed. Two independent
qPCR experiments for each set of samples were performed and
individual samples were run in triplicate. For each sample, the six
values (three from two separate reactions) were averaged to get an
expression value. The S.E.M. shown in Figure 1 represents the
variation from sample to sample (i.e. inter-mouse variation). Rds
primers amplify from transferred Rds and WT Rds, but not from the
Rds mutant allele. To confirm that Rds levels were not artificially
altered bythepresenceofundigestednanoparticle, control reactions
amplifying from the IRBP or CBA promoter regions were
performed and no product was detected. As an additional control,
a subset of samples was analyzed with Rds primers, but without the
addition of reverse transcriptase and no amplification was detected.
Antibodies
Antibodies were procured and used for immunohistochemistry
(IHC) and Western blot (WB) analysis as follows: mAB 3B6 (a kind
gift from Dr. R.S. Molday, University of British Columbia,
Vancouver, BC, Canada, IHC-1:100); RDS-CT recognizing both
endogenous Rds and, to a lesser extent, NMP (generated in-house,
IHC-1:100, WB-1:1000); anti-S-opsin, recognizing short-wave-
length mouse cone opsin (generated in-house, IHC-1:100, WB-
1:1000); mAb 1D4, recognizing rhodopsin (a generous gift from
Dr. R.S. Molday, WB-1:5000); Rom-1 (generated in-house, WB-
1:1000); and b-actin-HRP (Sigma/Aldrich, WB-1:5000).
Immunohistochemistry
Whole eyes were enucleated and fixed with phosphate-buffered
saline containing 4% paraformaldehyde at 4uC overnight. With
the exception of PI-2 eyes, the cornea and lens were removed and
the eye was returned to fixative for an additional two hours. The
eyes were cryoprotected by serial immersion in 15% and 30% (w/
v) sucrose solutions for at least two hours each. Individual eyes
were embedded in M1 embedding medium (Thermo Electron
Corporation, PA) and frozen on dry ice; frozen sections (10 mm
thickness) aligned with the vertical meridian were cut with a
cryostat (Leica) and collected on precleaned Superfrost-plusH
microscope slides (Fisher Scientific). The entire eye was sectioned,
and every sixth section was collected, enabling examination of
gene expression throughout the retina. For immunohistochemis-
try, all steps were carried out at room temperature as described
previously [13,47]. Staining controls included eyes from age-
matched NMP transgenic and WT mice, and slides on which
primary or secondary antibodies were omitted. Observation and
imaging were performed using an epifluorescent microscope
(AxiophotZeiss Ltd., Germany) and a spinning disk confocal
microscope (BX62 Olympus, Japan).
Protein detection by western blot
Western analysis was performed as reported previously
[24,35,49]. Dissected individual retinas were homogenized on
ice and solubilized (50 mM Tris, pH 7.8, 100 mM NaCl, 5 mM
EDTA, 0.05% SDS, 1 mM PMSF, 1% TX-100, 2.5% (v/v)
glycerol) for one hour at 4uC, then processed for SDS-PAGE and
subsequent Western blotting using 10–50 mg protein per lane (as
detected by Bradford assay; Bio-Rad). Blots were imaged using a
Kodak Image Station 4000R with Kodak MI software.
Electroretinography
Full-field electroretinography was performed as previously report-
ed [40] and analysis of the obtained electroretinograms (ERGs) was
performed as described in detail elsewhere [24,40] to quantitatively
assess rod- and cone-mediated visual function. Both scotopic (rod)
and photopic (cone) ERGs were recorded at PI-30, PI-60, and PI-120
on animals from all treatment groups and controls.
Histology and electron microscopy
Enucleated eyes were fixed, sectioned, and processed as
described previously [50]. Semithin sections collected through
the vertical meridian were stained with 1% (w/v) toluidine blue in
1% (w/v) sodium borate, coverslipped, and viewed with an
Olympus BH-2 microscope under 636. Digital images were
captured using a Nikon DXM1200 digital camera. Ultrathin
sections were stained with 2% uranyl acetate and lead citrate and
imaged using a JEOL 100CX electron microscope (80 KeV).
Statistical analyses
For qRT-PCR data, values are expressed as ratios (to uninjected
eye) of mean relative expression (6S.E.M.). Since ratios have an
inherently skewed (non-Gaussian) distribution, data were log-
transformed before undergoing one-way ANOVA. For ERG data,
nanoparticle-injected groups were compared with naked DNA-
injected groups. All groups passed the Kolmogorov-Smirnov test
for normality and P-values are from two-tailed, unpaired Student’s
t-tests. In cases where unequal variance was found (per an F-test),
Welch’s correction was applied (http://web.uccs.edu/lbecker/
SPSS/ttest.htm). Means and standard errors are reported in
Table 1 as indicated. To determine whether there was any
significant change in ERG amplitude over time, two-way ANOVA
with Bonferroni’s post-hoc test was used to compare treatment
groups at different ages. To determine whether naked DNA
caused any effect on function, one-way ANOVA with Bonferroni’s
post-hoc test was used to compare CBA-NMP naked DNA, IRBP-
NMP naked DNA, and saline injected groups.
Supporting Information
Figure S1 Transmission electron microscopy of compacted
DNA nanoparticles. During compaction of the NMP expression
plasmid, the presence of acetate as the lysine counterion produces
rod shaped particles with a minor diameter ,8 nm. Scale bar,
100 nM. EMs prepared as per Fink et al. (Fink TL, Klepcyk PJ,
Oette SM, Gedeon CR, Hyatt SL, et al. (2006) Plasmid size up to
20 kbp does not limit effective in vivo lung gene transfer using
compacted DNA nanoparticles. Gene Ther 13: 1048–1051.).
Found at: doi:10.1371/journal.pone.0005290.s001 (5.87 MB TIF)
Figure S2 Immunofluorescence demonstrating the specificity of
the 3B6 antibody for transgenic (NMP) RDS. Sections from WT
Nanoparticles in the rds
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PLoS ONE | www.plosone.org 9 April 2009 | Volume 4 | Issue 4 | e5290or NMP transgenic retinas were stained with RDS-CT (which
recognizes both transgenic and endogenous RDS) and mAB 3B6
(which recognizes only transgenic RDS).
Found at: doi:10.1371/journal.pone.0005290.s002 (9.47 MB TIF)
Figure S3 Transferred NMP is not expressed in saline injected
eyes. Frozen retinal sections from eyes collected at multiple ages
(PI-2 to PI-30) were immunostained for NMP (mAB 3B6, green)
and total RDS (RDS-CT, red) with a nuclear counterstain (DAPI,
blue). No NMP is detected in saline-injected control eyes, but
native RDS is detected only with RDS-CT antibody beginning at
PI-2 (P7), consistent with normal ocular development. Scale bars,
20 mm. N=3–5 mice per group.
Found at: doi:10.1371/journal.pone.0005290.s003 (9.92 MB TIF)
Figure S4 Morphometric analysis of nanoparticle injected eyes.
Rows of nuclei (top row) and OS thickness (bottom row) were
measured in 3–5 eyes per group. The average of 10 uninjected
control eyes is shown by the gray dashed line, 6standard deviation
(shaded in gray). Black lines represent results from two individual
nanoparticle injected animals. N, nasal side; T, temporal side. At
PI-30 no substantial changes in the number of ONL rows are
detected. CBA-NMP and IRBP-NMP injected animals show some
increase in OS layer thickness near the injection site. At PI-120
CBA-NMP injection has no effect on retinal morphometry, while
IRBP-NMP mediates moderate increases in both OS layer
thickness and the number of rows of ONL nuclei.
Found at: doi:10.1371/journal.pone.0005290.s004 (7.06 MB TIF)
Figure S5 IRBP promoter expression in rods and cones. Eyes
were collected and sectioned from transgenic mice expressing
NMP under the control of the IRBP promoter. 3B6 specifically
recognizes transgenic NMP (not endogenous RDS) and S-opsin
labels blue cone photoreceptor outer segments. Note the enhanced
3B6 immunoreactivity in cones (compared to rods) suggesting that
the IRBP promoter drives more gene expression in cones than in
rods. ROS, rod outer segments, COS, cone outer segments, IS,
inner segments. Scale bar, 10 mm.
Found at: doi:10.1371/journal.pone.0005290.s005 (3.45 MB TIF)
Text S1 Supplemental Methods
Found at: doi:10.1371/journal.pone.0005290.s006 (0.03 MB
DOC)
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